The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).

It's been 30 years since a new drug to delay kidney disease progression in adults with type 1 diabetes was successful in a clinical trial -- the last being the ACE inhibitor captopril in 1993 -- noted ...

Background The epidemiology and long-term healthcare utilisation associated with chronic kidney disease (CKD) among those ...

Patients taking ACE inhibitors and ARBs saw a 16% reduction in their risk of cancer progression (HR, 0.84; 95% CI, 0.71-0.99; ...

The approach could help clinicians who are “burdened with information overload” manage their patients, one expert says.

Commonly prescribed heart medications, including statins and diuretics, do not negatively affect the survival of ...

Guideline-directed medical therapy and dose titration are essential to improving outcomes in heart failure with reduced or mildly reduced ejection fraction.According to the CDC, 6.7 million U.S.

Commonly prescribed cardiovascular medications - such as statins, diuretics, and blood pressure drugs - appear to have little ...

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the ...

A renowned cardiologist has shared their top seven tips to follow to improve your heart health and prevent high blood ...

A safer -- and arguably better -- way to cash in on the anti-obesity drug market is to invest in a proven leader like Novo ...

Grinspoon noted that even incremental reductions in blood pressure incidence can translate into meaningful declines in cardiovascular events at the population level. In people living with HIV, who ...